Clinical Trial Update: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan, capecitabine, and oxaliplatin as first-line therapy for metastatic gastric or gastroesophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastrointestinal Neoplasm

Drugs mentioned

• Irinotecan, Capecitabine and Oxaliplatin

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Gastrointestinal Neoplasm, Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED